Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
Telix today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024).
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
Telix today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®, 89Zr- girentuximab) kidney cancer imaging).
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
Telix today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix’s development program will initially focus on the treatment of bladder cancer, rounding out its urology franchise, which includes late-stage therapeutic programs for kidney and prostate cancers.
Telix ADSs Commence Trading on Nasdaq
Telix announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol ‘TLX’.
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
Telix today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for the use of EZAG’s cyclotron-based systems to produce the alpha-emitting isotope, actinium-225 (225Ac). This provides Telix with both an additional commercial source of 225Ac and access to a platform technology that enables highly efficient, scalable isotope production for use in the development of next generation targeted alpha therapies (TATs), a strategic focus for Telix.
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
Telix today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialised diagnostic radiopharmaceuticals for Medicare Fee for Service patients in the hospital outpatient setting, beyond the transitional pass-through payment period (“pass-through”). This is a significant decision for patients and hospitals, with the change facilitating equitable access to advanced imaging agents for all patients into the future.
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®), an agent for the imaging of glioma. The application has been granted priority review and designated a PDUFA goal date of 26 April 2025, paving the way for a U.S. commercial launch in 2025.
Telix Files Form 20-F Registration Statement for Nasdaq ADS
Telix announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with the United States (U.S.) Securities and Exchange Commission (SEC) relating to a proposed listing of American Depository Shares (ADS), representing the Company’s ordinary shares, on the Nasdaq Stock Market (Nasdaq).
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
Telix today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3 2024).
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
Telix and RLS (USA) Inc., America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals, today announced an agreement by the Company to acquire RLS from its parent company, RLS Group Ltd. The acquisition significantly expands Telix’s North American manufacturing footprint and establishes the basis of a next generation radiometal production network to benefit Telix and select strategic commercial partners.